Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group

International Journal of Antimicrobial Agents

Volumn 39, Issue 4, 2012, Pages 317-320

  Conlon, J Michael ^a   Sonnevend, Agnes ^a   Pál, Tibor ^a   Vila Farrés, Xavier ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acinetobacter baumannii; Antimicrobial peptide; Colistin resistance; Frog skin

Indexed keywords

ALYTESERIN 1C; BREVININ 2 RELATED PEPTIDE; BREVININ 2 RELATED PEPTIDE ERA; CAERULEIN PRECURSOR FRAGMENT; COLISTIN; PEPTIDE GLYCINE LEUCINE AMIDE; PEPTIDE XT 7; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER NOSOCOMIALIS; ALPHA HELIX; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; ERYTHROCYTE MEMBRANE; HEMOLYSIS; HUMAN; HUMAN CELL; LC 50; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ANURA; COLISTIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; ERYTHROCYTES; HEMOLYSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; SKIN;

EID: 84858278345     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.12.005     Document Type: Article

References (30)

1. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 2008;32: 106-19.
2. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84. (Pubitemid 47519332)
3. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007;5:939-51. (Pubitemid 350131182)
4. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254-63. (Pubitemid 351589912)
5. Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008;9:587-99. (Pubitemid 351425386)
6. Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents 2011;37: 102-9.
7. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25. (Pubitemid 40023341)
8. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski 3rd A, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;30:1279-91.
9. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50. (Pubitemid 44396396)
10. Conlon JM, Sonnevend A. Clinical applications of amphibian antimicrobial peptides. J Med Sci 2011;4:62-72.
11. Perron GG, Zasloff M, Bell G. Experimental evolution of resistance to an antimicrobial peptide. Proc Biol Sci 2006;273:251-6. (Pubitemid 46768100)
12. Vila-Farres X, Garcia de la Maria C, López-Rojas R, Pachón J, Giralt E, Vila J. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect 2011;18, doi:10.1111/j.1469-0691.2011.03581.x Epub ahead of print.
13. Conlon JM, Al-Ghaferi N, Ahmed E, Meetani MA, Leprince J, Nielsen PF. Orthologs of magainin, PGLa, procaerulein-derived, and proxenopsin-derived peptides from skin secretions of the octoploid frog Xenopus amieti (Pipidae). Peptides 2010;31:989-94.
14. Al-Ghaferi N, Kolodziejek J, Nowotny N, Coquet L, Jouenne T, Leprince J, et al. Antimicrobial peptides from the skin secretions of the South-East Asian frog Hylarana erythraea (Ranidae). Peptides 2010;31:548-54.
15. Conlon JM, Ahmed E, Pal T, Sonnevend A. Potent and rapid bactericidal action of alyteserin-1c and its [E4K] analog against multidrug-resistant strains of Acine-tobacter baumannii. Peptides 2010;31:1806-10.
16. Conlon JM, Ahmed E, Condamine E. Antimicrobial properties of brevinin-2- related peptide (B2RP) and its analogs: efficacy against multidrug-resistant Acinetobacter baumannii. Chem Biol Drug Des 2009;74:488-93.
17. Conlon JM, Galadari S, Raza H, Condamine E. Design of potent, non-toxic antimicrobial agents based upon the naturally occurring frog skin peptides, ascaphin-8 and peptide XT-7. Chem Biol Drug Des 2008;72:58-64. (Pubitemid 351852774)
18. Nemec A, Krizova L, Maixnerova M, van der Reijden TJ, Deschaght P, Passet V, et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res Microbiol 2011;162:393-404.
19. Fernández-Reyes M, Rodríguez-Falcón M, Chiva C, Pachón J, Andreu D, Rivas L. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 2009;9:1632-45.
20. Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández-Cuenca F, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009;30:257-63.
21. Clinical and Laboratory and Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2008.
22. Subasinghage AP, O'Flynn D, Conlon JM, Hewage CM. Conformational and membrane interaction studies of the antimicrobial peptide alyteserin-1c and its analogue [E4K]alyteserin-1c. Biochim Biophys Acta 2011;1808:1975-84.
23. Almeida PF, Pokorny A. Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics. Biochemistry 2009;48:8083-93.
24. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related antibiotics. Annu Rev Biochem 1977;46:723-63.
25. Peterson AA, Hancock RE, McGroarty EJ. Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J Bacteriol 1985;164:1256-61. (Pubitemid 16207271)
26. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010;54:4971-7.
27. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009;53:3628-34.
28. Hancock RE, Bell A. Antibiotic uptake into Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1988;7:713-20. (Pubitemid 19017153)
29. Saugar JM, Rodríguez-Hernández MJ, de la Torre BG, Pachón-Ibañez ME, Fernández-Reyes M, Andreu D, et al. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother 2006;50:1251-6.
30. Sebeny PJ, Riddle MS, Petersen K. Acinetobacter baumannii skin and soft-tissue infection associated with war trauma. Clin Infect Dis 2008;47:444-9.